Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Lucie Barthod, Jean-Guillaume Lopez, Christophe Curti, Charléric Bornet, Manon Roche, Marc Montana & Patrice Vanelle. (2018) News on therapeutic management of MDR-tuberculosis: a literature review. Journal of Chemotherapy 30:1, pages 1-15.
Read now
Read now
Zhi Huang, Shuai Zhang, Yaping Shen, Weixin Liu, Jipu Long & Shi Zhou. (2016) Influence of MDR1 methylation on the curative effect of interventional embolism chemotherapy for cervical cancer. Therapeutics and Clinical Risk Management 12, pages 217-223.
Read now
Read now
T. V. A. Nguyen, T. B. T. Cao, O. W. Akkerman, S. Tiberi, D. H. Vu & J. W. C. Alffenaar. (2016) Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Review of Clinical Pharmacology 9:8, pages 1025-1037.
Read now
Read now
Sabine Bélard, Charlotte C Heuvelings, Saskia Janssen & Martin P Grobusch. (2015) Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Review of Anti-infective Therapy 13:5, pages 535-553.
Read now
Read now
Peter Norman. (2015) Orphan drug approvals of 2014: Europe and the United States. Expert Opinion on Orphan Drugs 3:4, pages 445-455.
Read now
Read now
Articles from other publishers (17)
Fei Yan, Shengui He, Xiuyan Han, Jiayue Wang, Xiangge Tian, Chao Wang, Tony D. James, Jingnan Cui, Xiaochi Ma & Lei Feng. (2022) High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis. Biosensors and Bioelectronics 216, pages 114606.
Crossref
Crossref
Vitaly Litvinov, Marina Makarova, Dmitry Kudlay, Nikolai Nikolenko & Julia Mikhailova. (2021) In vitro activity of bedaquiline against Mycobacterium avium complex. Journal of Medical Microbiology 70:10.
Crossref
Crossref
Sharon Isralls, Kathy Baisley, Eric Ngam, Alison D Grant & James Millard. (2021) QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infectious Diseases 8:8.
Crossref
Crossref
Vishwas Pardhi, Geetanjali Pant & S. J. S. Flora. (2020) RP-HPLC method development and validation for bedaquiline fumarate to evaluate its forced degradation behaviour and stability in official dissolution media. Future Journal of Pharmaceutical Sciences 6:1.
Crossref
Crossref
Norimitsu Hariguchi, Xiuhao Chen, Yohei Hayashi, Yoshikazu Kawano, Mamoru Fujiwara, Miki Matsuba, Hiroshi Shimizu, Yoshio Ohba, Izuru Nakamura, Ryuki Kitamoto, Toshio Shinohara, Yukitaka Uematsu, Shunpei Ishikawa, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura & Makoto Matsumoto. (2020) OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Hamish S. Sutherland, Amy S.T. Tong, Peter J. Choi, Adrian Blaser, Scott G. Franzblau, Christopher B. Cooper, Anna M. Upton, Manisha Lotlikar, William A. Denny & Brian D. Palmer. (2020) Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology. Bioorganic & Medicinal Chemistry 28:1, pages 115213.
Crossref
Crossref
Hamish S. Sutherland, Amy S.T. Tong, Peter J. Choi, Adrian Blaser, Daniel Conole, Scott G. Franzblau, Manisha U. Lotlikar, Christopher B. Cooper, Anna M. Upton, William A. Denny & Brian D. Palmer. (2019) 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel. Bioorganic & Medicinal Chemistry 27:7, pages 1292-1307.
Crossref
Crossref
Adrian Blaser, Hamish S. Sutherland, Amy S.T. Tong, Peter J. Choi, Daniel Conole, Scott G. Franzblau, Christopher B. Cooper, Anna M. Upton, Manisha Lotlikar, William A. Denny & Brian D. Palmer. (2019) Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline. Bioorganic & Medicinal Chemistry 27:7, pages 1283-1291.
Crossref
Crossref
Chiara Borsari, Stefania Ferrari, Alberto Venturelli & Maria Paola Costi. (2017) Target-based approaches for the discovery of new antimycobacterial drugs. Drug Discovery Today 22:3, pages 576-584.
Crossref
Crossref
Morris Muliaditan, Geraint R. Davies, Ulrika S.H. Simonsson, Stephen H. Gillespie & Oscar Della Pasqua. (2017) The implications of model-informed drug discovery and development for tuberculosis. Drug Discovery Today 22:3, pages 481-486.
Crossref
Crossref
Moloko C. Cholo, Maborwa T. Mothiba, Bernard Fourie & Ronald Anderson. (2017) Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. Journal of Antimicrobial Chemotherapy 72:2, pages 338-353.
Crossref
Crossref
Julia Robertson, James Dalton, Siouxsie Wiles, Marija Gizdavic-Nikolaidis & Simon Swift. (2016) The tuberculocidal activity of polyaniline and functionalised polyanilines. PeerJ 4, pages e2795.
Crossref
Crossref
Aníbal M. Reyes, Diego S. Vazquez, Ari Zeida, Martín Hugo, M. Dolores Piñeyro, María Inés De Armas, Darío Estrin, Rafael Radi, Javier Santos & Madia Trujillo. (2016) PrxQ B from Mycobacterium tuberculosis is a monomeric, thioredoxin-dependent and highly efficient fatty acid hydroperoxide reductase. Free Radical Biology and Medicine 101, pages 249-260.
Crossref
Crossref
Qionghong Duan, Zi Chen, Cong Chen, Zhengbin Zhang, Zhouqin Lu, Yalong Yang & Lin Zhang. (2016) The Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-Analysis. PLOS ONE 11:2, pages e0148041.
Crossref
Crossref
Kei Katsuno, Jeremy N. Burrows, Ken Duncan, Rob Hooft van Huijsduijnen, Takushi Kaneko, Kiyoshi Kita, Charles E. Mowbray, Dennis Schmatz, Peter Warner & B. T. Slingsby. (2015) Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery 14:11, pages 751-758.
Crossref
Crossref
Rita Banzi, Chiara Gerardi, Vittorio Bertele'Silvio Garattini. (2015) Approvals of drugs with uncertain benefit–risk profiles in Europe. European Journal of Internal Medicine 26:8, pages 572-584.
Crossref
Crossref
Olga B. Bekker, Dmitry N. Sokolov, Olga A. Luzina, Nina I. Komarova, Yuriy V. Gatilov, Sofia N. Andreevskaya, Tatiana G. Smirnova, Dmitry A. Maslov, Larisa N. Chernousova, Nariman F. Salakhutdinov & Valery. N. Danilenko. (2015) Synthesis and activity of (+)-usnic acid and (−)-usnic acid derivatives containing 1,3-thiazole cycle against Mycobacterium tuberculosis. Medicinal Chemistry Research 24:7, pages 2926-2938.
Crossref
Crossref